The PROSERA Study is a Phase 3 clinical research study designed to help researchers understand whether an inhaled investigational product may be an effective and safe future treatment for adults with pulmonary arterial hypertension.
The PROSERA Study is a randomized double-blind clinical trial, which means each participant will be randomly allocated to receive either the study drug or placebo. In order to test one against the other, neither the participant nor the study doctor will know which treatment they will receive. This is standard practice, it helps prevent bias when doctors evaluate the participant outcomes, improving the reliability of the study results.
Pulmonary arterial hypertension is a rare, progressive disease that occurs when there is an overgrowth of cells in the small blood vessels that supply the lungs. This overgrowth causes the arteries to become narrower and stiffer, disrupting the flow of blood through the heart and lungs.
